These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36712872)

  • 1. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
    Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
    Front Genet; 2022; 13():1068462. PubMed ID: 36712872
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Zheng H; Long G; Zheng Y; Yang X; Cai W; He S; Qin X; Liao H
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358765
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wang Y; Wen H; Sun D
    Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
    Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
    Front Immunol; 2022; 13():998266. PubMed ID: 36248785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
    Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
    Front Genet; 2022; 13():938510. PubMed ID: 36171879
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
    Ma P; Sun W
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration.
    Wu H; Geng Q; Shi W; Qiu C
    Apoptosis; 2024 Apr; 29(3-4):536-555. PubMed ID: 38066393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
    Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
    BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 17. Pan-cancer analysis of the disulfidptosis-related gene
    Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
    Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERH Impacts Patient Prognosis and Tumor Immune Microenvironment: A Pan-Cancer Analysis.
    Gong Q; Li Q; Shen X; Xu Z
    Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38584561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis reveals NAA50 as a cancer prognosis and immune infiltration-related biomarker.
    Fang T; Wang D; Li R; Yu W; Tian H
    Front Genet; 2022; 13():1035337. PubMed ID: 36568377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.